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CONTEMPORARY REVIEW
Complex Relationship Between Cardiac 
Fibroblasts and Cardiomyocytes in Health 
and Disease
Caitlin Hall , MSci; Katja Gehmlich, PhD; Chris Denning , PhD*; Davor Pavlovic , PhD*
ABSTRACT: Cardiac fibroblasts are the primary cell type responsible for deposition of extracellular matrix in the heart, provid-
ing support to the contracting myocardium and contributing to a myriad of physiological signaling processes. Despite the 
importance of fibrosis in processes of wound healing, excessive fibroblast proliferation and activation can lead to pathological 
remodeling, driving heart failure and the onset of arrhythmias. Our understanding of the mechanisms driving the cardiac fibro-
blast activation and proliferation is expanding, and evidence for their direct and indirect effects on cardiac myocyte function 
is accumulating. In this review, we focus on the importance of the fibroblast- to- myofibroblast transition and the cross talk of 
cardiac fibroblasts with cardiac myocytes. We also consider the current use of models used to explore these questions.
Key Words: arrhythmias ■ cardiac fibroblasts ■ cardiomyocytes ■ fibrosis ■ heart failure ■ myofibroblast
Because of aging populations and lifestyle changes, the total number of deaths caused by cardiovascular diseases (CVDs) is increasing, 
by ≈21% from 2007 to 2017.1 High mortality rates as 
well as a high level of morbidity contribute to the high 
economic burden of CVDs.2 Many of these deadly and 
debilitating CVDs are associated with cardiac fibrosis, 
which can be classified as either diffuse interstitial or 
replacement fibrosis.3 Replacement fibrosis occurs 
immediately following cardiac injury, such as myocar-
dial infarction (MI), to form a fibrotic scar preventing 
rupture of the myocardium.3,4 Interstitial fibrosis is as-
sociated with inflammation and more chronic condi-
tions, such as cardiomyopathies or hypertension, and 
if the underlying condition is left untreated, results in 
irreversible replacement fibrosis.3– 5 Cardiac fibrosis 
contributes to both electrical and structural remodel-
ing of the heart, which ultimately leads to decreased 
cardiac function, heart failure, and arrhythmias.4,6– 8 
The relationship between fibrosis and CVDs has been 
the subject of multiple studies. However, with no ef-
ficient treatments directly targeting cardiac fibrosis, 
it presents an ever- growing clinical challenge.9,10 The 
fibrotic process is mediated by activation of cardiac 
fibroblasts (cFbs), an important nonexcitatory cell pop-
ulation in the heart, responsible for deposition of extra-
cellular matrix (ECM) in health and disease. cFbs can 
influence cardiac function through direct and indirect 
effects on cardiomyocytes.11– 13 In this review, we sum-
marize the current understanding of the interactions 
between cFbs and cardiomyocytes and discuss the 
key questions remaining.
CARDIAC FIBROBLASTS
The human heart is composed of 5 major cell 
types: cardiomyocytes, fibroblasts, endothelial 
cells, macrophages, and smooth muscle cells.14– 16 
Cardiomyocytes contribute roughly 30% to 40% by 
number and roughly 65% to 80% by volume in the adult 
mammalian heart.16– 21 Recent single- cell sequencing 
studies highlight considerable heterogeneity between 
the different regions of the human heart, with ventricles 
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having distinct cellular signatures compared with atria 
(47.1% cardiomyocytes compared with 31.1%, respec-
tively).16,20 Reports on proportion of cFbs in heart differ, 
from circa 20% to 60% in rats and humans.6,15,16,19 cFb 
numbers increase with development, aging, and dis-
ease. Banerjee et al showed that, in both rats and mice, 
the number of fibroblasts increases postnatally until 
adulthood is reached (≈30% to ≈64% in rat and ≈10% 
to ≈25% in mouse).15 An increase in cFbs has also been 
demonstrated in heart failure and following MI.14,22,23
Comparison of transcriptomes has revealed more 
similarities between cFbs and cardiomyocytes than 
between other fibroblast cell types.24,25 In addition, use 
of single- cell RNA sequencing has identified several 
subpopulations of cFbs within the heart, displaying 
distinct genetic signatures.16 As mesenchymal cells 
present in every tissue in our body, these subpopula-
tions may be indicative of the various possible cFb lin-
eages.6,16 In the heart, cFbs are primarily derived from 
the proepicardium, but can also arise by epithelial- 
to- mesenchymal and endothelial- to- mesenchymal 
transition.6,26 Because of this heterogeneity and their 
ubiquitous nature, markers specific to cFbs are still 
lacking. Vimentin is often used alongside specific mor-
phological properties of cFbs, such as the lack of a 
basement membrane. Some reports have used FSP1 
(fibroblast- specific protein 1) and discoidin domain re-
ceptor to identify cFbs, but these are also found in leu-
kocytes and fibrocytes, respectively.6,27
Regardless of origin, resident cFbs are dispersed 
throughout the heart as strands and sheets that sit be-
tween cardiac muscle fibers acting as a scaffold.28,29 
Their main function is to maintain the ECM through 
regulation of matrix metalloproteinases and tissue in-
hibitors of metalloproteinases, and therefore mediate 
secretion and degradation of collagen.30 During dis-
ease or injury (eg, following MI), cFbs undergo a transi-
tion from fibroblast to myofibroblast.6,31 This activated 
phenotype is described as having a spindle shape, 
increased proliferation, expression of α- smooth 
muscle actin (α- SMA), and increased production of 
collagen.32,33 Single- cell sequencing in mouse hearts 
further defined these differences between the acti-
vated myofibroblast and nonactivated cFb. They found 
≈30 genes differentially expressed between the 2 cell 
types, including periostin and collagens 1 and 3, all 
known to be associated with the myofibroblast.34
The main role of this cell type is wound healing 
and repair. Following MI, formation of a fibrotic scar, 
in place of necrotic tissue, prevents rupture of the 
myocardium.4,22 The expression of α- SMA stress fi-
bers provides these cells with the ability to contract. 
This causes shrinkage of the fibrotic scar and pro-
duces tension, which, in turn, increases the stiffness 
of the myocardium.32,35– 37 Although initially beneficial 
for maintenance of cardiac function and prevention of 
heart rupture, long- term effects of excessive fibrosis 
are detrimental (see section on Cross Talk Between the 
Myofibroblast and the Cardiomyocyte below).
Structural and electrical remodeling of the myo-
cardium, attributed to chronic and proinflammatory 
conditions, such as hypertension, is commonly as-
sociated with cardiac fibrosis.28,38,39 Inflammation has 
been demonstrated to lead to cardiac fibrosis via acti-
vation of profibrotic signaling cascades via interleukin 
6 (IL- 6) (see section on Interleukin 6 below).40 Stiffness 
itself can activate cFbs, leading to transition to myo-
fibroblasts (Figure  1). Myofibroblasts themselves can 
secrete further profibrotic factors, driving progres-
sion to the kind of fibrosis seen following MI.28,32,41,42 
Alongside increased stiffness, fibrosis has also been 
observed to slow conduction and disrupt electrical 
wave propagation. Ultimately, these factors contribute 
to decreased cardiac function and increased suscepti-
bility to arrhythmias.43
The transition from cFb to myofibroblast is a multifac-
torial process mediated by several factors (Figure 1).28,37 
Transforming growth factor- β (TGF- β) has been shown 
in several independent studies to be directly involved 
in this transition process.44– 46 Myofibroblasts, once 
activated, can themselves secrete TGF- β, thus cre-
ating a detrimental positive feedback loop leading 
to sustained fibrosis.47– 49 The importance of tensile 
strength and mechanical stress in the activation of 
myofibroblasts has also been demonstrated (see sec-
tion on Cross Talk Between the Myofibroblast and the 
Cardiomyocyte for more detail).32,48,50 Perhaps not sur-
prisingly, cFb activation can modulate cardiomyocyte 
function, and several modes of cFb- cardiomyocyte 
communication have been uncovered.
MECHANISMS OF CFB- 
CARDIOMYOCYTE COMMUNICATION
In the 1980s, multiple studies demonstrated cell- cell 
interactions between excitatory and nonexcitatory cells 
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in the heart. These were shown to be mediated via 
paracrine signaling and/or direct contacts between the 
cells.51,52 From the mid- 2000s, there has been more 
focus on the effects of the nonexcitatory stromal cells 
on the electrophysiological features of the heart, with 
changes to conduction velocity and membrane de-
polarization observed during coculture.53 This is per-
haps not surprising considering that they make up a 
significant proportion of the total cell count.54 More re-
cently, multiple studies have identified that electrotonic 
communication occurs between cFbs and cardiomyo-
cytes. This was demonstrated using cultured as well 
as freshly isolated cFbs in vitro, and in animal disease 
models in vivo.13,53,55,56 The interaction and communi-
cation between cardiomyocytes and cFbs was shown 
to occur through several different modes (Figure  2). 
These include heterologous coupling through the for-
mation of gap junctions or membrane nanotubes, and 
via mechanical forces and paracrine signaling.13,53,57,58 
However, the question still remains as to whether these 
coupling events occur in vivo in humans.
COMMUNICATION VIA GAP 
JUNCTIONS
Gap junctions are considered the main mechanism 
for electrotonic coupling in the heart.59 They are ion 
channels that allow propagation of electrical signals 
between neighboring cells. Gap junctions are formed 
through the combination of 2 hemichannels, which 
are either homomeric or heteromeric. Depending on 
the composition of the 2 hemichannels, the junction 
will be either homotypic or heterotypic.60 The com-
bination of different connexins has demonstrated 
varying levels of channel permeability.61,62 Connexin 
40, connexin 43 (Cx43), and connexin 45 are the 3 
main connexin subtypes found in the heart. Cx43 
is the most widely expressed across the atrial and 
ventricular myocardium in both cardiomyocytes and 
cFbs.59,60
Changes in the expression of Cx43, and in some 
cases connexin 45, have been observed to affect car-
diac function. Studies have shown that the aging heart 
is accompanied by abnormalities in expression and 
distribution of Cx43.63,64 When 10- week- old rat hearts 
were compared with those from 2- year- old rats, a de-
creased intensity of Cx43 expression was seen in the 
left ventricles.64 Similar results were also seen in the 
atria of guinea pig hearts, accompanied by deteriora-
tion of adhesive junctions as well as gap junctions.63 
Furthermore, this age- related decrease in Cx43 has 
been linked to slowed conduction velocity.65 Together, 
these results show that through mediating expression 
of Cx43, aging can lead to conduction slowing and in-
creased risk of arrhythmias.
These changes have also been observed following 
cardiac injury. Vasquez et al13 revealed that Cx43 and 
connexin 45 are present at cardiomyocyte- fibroblast 
contact points in neonatal rat cells. In a model of car-
diac injury, an increase in expression of Cx43 in cFbs, 
along with an observed increase in functional coupling 
between cardiomyocytes and cFbs, was detected. 
The same study also identified that myofibroblasts 
isolated from infarcted hearts, when cocultured with 
Figure 1. Resident cardiac fibroblasts (cFbs) derive from endothelial- to- mesenchymal or 
epithelial- to- mesenchymal transition.
Injury to the myocardium initiates signaling pathways that trigger the activation of cFbs to myofibroblasts 
(MyoFbs). Loss of structural integrity via cardiomyocyte (CM) death also creates mechanical stress that 
mediates cFb to MyoFb activation. Consequences of MyoFb activation vary between repair and disease 
processes. There are multiple mechanisms for activation, including mechanical stimuli and paracrine 
factors, such as transforming growth factor- β (TGF- β) and angiotensin II (Ang II), from a variety of different 
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cardiomyocytes, decreased conduction velocities 
of the action potential and reduced action potential 
duration at 70% repolarization. More important, the 
authors showed that the effects on conduction and 
action potential duration were cFb density dependent, 
thus pointing toward a potential role in driving electro-
physiological heterogeneity across the heart and thus 
contributing to increase in arrhythmias.13 This cFb den-
sity dependency on cardiomyocyte electrophysiolog-
ical features was also shown in modeling studies by 
Sanchez et al, with effects being most prominent in the 
left atrial pulmonary vein myocardium, a common site 
of atrial ectopy.66
Zhang et al demonstrated in a mouse model that 
cFbs are activated following MI. Interestingly, these 
observations were apparent even in remote regions, 
away from the site of injury.67 This implicates myofibro-
blasts in the postinfarct remodeling process, as estab-
lished by other groups.67,68 More important, Zhang et 
al demonstrated that cFbs from infarcted hearts dis-
played increased expression of Cx43 and intercellular 
cardiomyocyte coupling. However, in contrast, cardio-
myocytes from these models exhibited downregulation 
and redistribution of Cx43 following MI. Decreased ex-
pression of Cx43 in cardiomyocytes has been shown to 
lead to increased propensity for abnormal conduction 
and susceptibility to arrhythmias.67,69 These data to-
gether suggest that cFbs may be maintaining elec-
trical coupling, to some extent, to preserve cardiac 
function.67 Whether this adaptive process is ultimately 
detrimental to the heart requires further confirmation. 
With the availability of human induced pluripotent stem 
cell– derived cFbs and cardiomyocytes, there is an op-
portunity, and a clear need, for further studies robustly 
examining the interaction and effects of nonactivated 
and activated cFbs on cardiomyocyte electrophysio-
logical features in human cell lines.70
COMMUNICATION VIA MEMBRANE 
NANOTUBES
Another mechanism that facilitates cFb- 
cardiomyocyte communication is that of membrane 
nanotubes. This was established as a novel interac-
tion by He et al, who demonstrated that membrane 
nanotubes, through the exchange of Ca2+, could facili-
tate both long- and short- range connectivity between 
cardiomyocytes and cFbs and therefore regulate car-
diac contractility.57 Membrane nanotubes are long, 
thin, membrane- bound connections that consist of 
F- actin and, in some cells, microtubules.71,72 They are 
Figure 2. Figure depicting cardiomyocyte (CM)– myofibroblast (MyoFb) communcations.
Gap junctions are present at distal junctions between CMs as well as elsewhere between CMs and 
MyoFbs. Gap junctions and membrane nanotubes allow exchange of molecules between the cytoplasms 
of cells. Paracrine factors secreted by cells bind receptors on neighbouring membranes, initiating 
signaling pathways. cFb indicates cardiac fibroblast.Dow
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suggested to help to control structural connectivity 
between cardiomyocytes and cFbs but also allow di-
rect communication via the exchange of organelles, 
vesicles, and ions, such as Ca2+, across distances 
of up to several micrometers. In theory, membrane 
nanotubes have the advantage over gap junctions, 
which are limited to transfer of molecules of <1.2 kDa 
and only where cells are in close proximity.57 Although 
membrane nanotubes have been identified in both 
cardiomyocytes and cFbs in vivo,57,72 the proposed 
effects on contractility have not, and more research 
is required to identify their role and contributions to 
mediating electrical signals in the heart.
COMMUNICATION VIA PARACRINE 
SIGNALING
Cardiomyocytes and cFbs can also interact indirectly 
via paracrine signaling.73 Considering that fibrosis 
is also demonstrated in areas remote to the injured 
myocardium, it is perhaps not surprising that par-
acrine factors may be involved in this process.74 To 
further investigate this concept, several groups have 
used separated coculture methods, using physical 
inserts to separate the 2 cell types within the same 
well or cFb conditioned medium harvested from cul-
tured cFbs.13,75,76 These have demonstrated the in-
volvement of paracrine mediators independently and 
alongside that of mechanical stress or physical cou-
pling on electrophysiological activity.13,75 LaFramboise 
et al showed that, following the addition of cFb con-
ditioned medium, cardiomyocyte hypertrophy as well 
as reduction of spontaneous contractions were ob-
served in neonatal cardiomyocytes.75 Vasquez et al13 
built on this work by comparing effects of conditioned 
media obtained from normal hearts and hearts with 
MI. They showed that conditioned medium from cFbs 
isolated from rat hearts with MI leads to slowed con-
duction velocities and a shortened action potential 
duration when compared with normal cFbs.13
There is growing evidence in support of cFb- 
produced paracrine factors playing a role in modula-
tion of cardiac function and arrhythmogenesis. Many 
of these paracrine factors involved are known, how-
ever, mechanisms driving the observed changes in 
cardiac function and are under investigation. These will 
be discussed in the next section.
CROSS TALK BETWEEN THE 
MYOFIBROBLAST AND THE 
CARDIOMYOCYTE
Following identification of such communications be-
tween cFbs- cardiomyocytes, the importance of 
defining the consequences of these mechanisms be-
came apparent. The primary focus to date has been 
on TGF- β. An important mediator in the differentia-
tion of cFb to myofibroblast, it has also been shown 
to have direct effects on cardiomyocyte function.47,72,77 
However, there is also evidence for the involvement of 
angiotensin II (Ang II), IL- 6, and mechanical stimuli in 
the communication processes.72,73
ROLE OF TGF- β
TGF- β is an important cytokine involved in many 
different cellular processes, including proliferation, 
differentiation, and migration.77 Its expression is al-
tered by several stimuli, such as mechanical stretch, 
hormones, and cytokines. In the heart, it is the driv-
ing force for myofibroblast activation and is therefore 
crucial during injury and wound healing.44,78 TGF- β 
receptor stimulation activates multiple downstream 
pathways, via both small mothers against decapen-
taplegic (Smad)– (Figure 3) and non– Smad- mediated 
transcription (Figure  4), to induce cFb proliferation, 
collagen synthesis, and myofibroblast activation.4,47,79 
Multiple studies have shown that TGF- β activates 
cFbs, at least to some extent, demonstrated by 
the expression of α- SMA fibers and a contractile 
phenotype.4,25,47
In 1988, Thompson et al reported the importance 
of TGF- β in cardiac disease in rats. They showed a 
marked increase in TGF- β in cardiomyocytes follow-
ing MI with increased localization to the border zone.80 
Several studies since then have reported TGF- β con-
tributing to both fibrotic and hypertrophic effects 
in the myocardium, both in vitro and in vivo.4,73,77 
Furthermore, higher levels of TGF- β are detected in 
hypertrophic hearts and in heart failure models.22,81 
These effects have been identified in direct coculture 
with cFbs and myofibroblasts and through the use of 
cFb/myofibroblast conditioned medium. In the pres-
ence of a TGF- β receptor inhibitor, these effects were 
reduced or even reversed. These studies clearly high-
light the role of TGF- β in profibrotic and prohypertro-
phic processes.73,82
Nakajima et al also observed the effects of TGF- β to 
be more prominent in the atria compared with the ven-
tricles. Through use of models with constitutive TGF- β 
activity, they concluded that TGF- β alone was not suf-
ficient in promoting ventricular fibrosis in their mouse 
model.77 Rahmutula et al later built on this work using 
a similar model. They observed an increased expres-
sion in TGF- β signaling proteins in both atria and ven-
tricles, although expression of fibrotic genes was only 
increased in the atria. This expression was associated 
with an increased atrial susceptibility to fibrosis and 




 http://ahajournals.org by on M
arch 29, 2021
J Am Heart Assoc. 2021;10:e019338. DOI: 10.1161/JAHA.120.019338 6
Hall et al Cardiomyocyte- Cardiofibroblast Cross Talk
atrial tissue.83 Interestingly, it has also been demon-
strated that TGF- β maintains a positive feedback loop 
by acting on cardiomyocytes to sustain its own ex-
pression and maintain myofibroblast proliferation.73,84 
Competitive inhibition of TGF- β receptors can prevent 
the cFb activation process.22 Several independent 
studies have explored targeting TGF- β signaling as a 
potential antifibrotic therapeutic strategy. Kuwahara 
et al observed, in pressure overloaded mouse hearts, 
that fibrosis could be decreased using an anti– TGF- β 
neutralizing antibody.49 Similarly, Khalil et al demon-
strated that deletion of Smad2/3 attenuated the fi-
brotic response in pressure overloaded mouse hearts. 
However, increased mortality in TGF- β receptor knock-
down models and following long- term pharmacological 
inhibition after MI limits its therapeutic use.22,44
Despite this, a study by Davies et al further impli-
cated non- Smad signaling in atrial remodeling and 
arrhythmogenesis, specifically with age. Through 
use of a conditional mouse knockdown of Mkk4, they 
demonstrated MKK4 as a negative regulator of TGF- β 
signaling through activation of the JNK pathway. They 
showed that, with age and with Mkk4 deletion, there 
were significantly greater levels of fibrotic tissue, 
TGF- β1 expression, TGF- β receptor expression, and 
effects on matrix metalloproteinase and tissue inhib-
itor of metalloproteinase expression levels, provid-
ing a substrate for arrhythmogenesis. Furthermore, 
they discovered that, in patients with atrial fibrillation, 
there were decreased levels of MKK4.85
More recently, TGF- β has also been linked to the 
WNT signaling pathway in the context of fibrosis and 
Figure 3. Schematic of transforming growth factor-­β (TGF- β) activation via small mothers 
against decapentaplegic (Smad) signaling.
TGF- β binds its receptor, initiating phosphorylation (p) of Smad2/3. This complex then binds Smad4 
and translocates to the nucleus to induce transcription of target genes involved in proliferation, collagen 
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cardiac tissue remodeling.86 Several groups have ob-
served a role for WNT proteins in the activation of myo-
fibroblasts. Blyszczuk et al demonstrated this through 
the suppression of TGF- β– mediated myofibroblast ac-
tivation by blocking WNT signaling.87 Others have ob-
served stimulation of proliferation and upregulation of 
profibrotic genes through activation of the WNT path-
way.86,88,89 These data, together with those of Davies 
et al,85 suggest that although TGF- β itself may not be 
an appropriate target for pharmacological intervention, 
deciphering downstream targets could in fact provide 
new avenues for treatment.
The influence of TGF- β on ionic handling in the 
heart is less well defined. In coculture with cardiomy-
ocytes, both cFbs (defined as α- SMA– negative Fbs) 
and myofibroblasts have been reported to alter Ca2+ 
Figure 4. Schematic of transforming growth factor- β (TGF- β) activation via noncanonical (small 
mothers against decapentaplegic– independent) signaling.
TGF- β binds its receptor, initiating activation of Ras or TAK1 and further downsteam activation of 
extracellular signal- regulated kinase (ERK), JNK, or p38. This leads to promotion of transcription factors 
(TFs) and the transcription of target genes involved in myofibroblast (MyoFb) activation, fibrosis, and 
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transients. Myofibroblasts decreased Ca2+ transient 
amplitudes, whereas surprisingly, cFbs increased 
them. This effect was blocked by a TGF- β receptor 
inhibitor. TGF- β treatment of cardiomyocytes alone 
was not able to recapitulate the effects seen in co-
culture systems, indicating that TGF- β itself does not 
drive these Ca2+ transient alterations.73 Kaur et al ob-
served a peak Na+ current increase of ≈40% follow-
ing exposure to TGF- β. TGF- β effects on the current 
magnitude were voltage independent, and these ef-
fects were reversed in presence of a TGF- β neutral-
izing antibody.76 Whether these effects alter action 
potential morphological features and conduction or 
whether TGF- β leads to changes in intracellular Na+ 
concentrations is unclear.
The effects of TGF- β on cardiac pathogene-
sis have been recognized for many years through 
promotion of fibrosis and cardiomyocyte hypertro-
phy.49,81,85 The precise role of TGF- β in cardiac dis-
ease is only now becoming more evident. Numerous 
studies and the modern - omics approaches have 
highlighted TGF- β involvement in the modulation of 
multiple signaling pathways, important in activating 
the myofibroblast.44,90,91 Novel use of computer mod-
eling has enabled generation of in silico fibrosis mod-
els,92 allowing dissection of the TGF- β signalosome 
and potentially identification of novel downstream 
targets for antifibrotic therapy.
ANGIOTENSIN II
Ang II is a hormone that acts as part of the renin- 
angiotensin system and is involved in regulating blood 
pressure and sodium homeostasis.93,94 Inhibition of 
Ang II signaling through use of angiotensin- converting 
enzyme inhibitors has long been used to treat hyper-
tension.95 However, evidence over the years has also 
suggested an important role for Ang II in ventricular 
remodeling following cardiac injury.96,97 Schieffer et al 
showed that, by blocking angiotensin receptors and by 
angiotensin- converting enzyme inhibition, ventricular 
remodeling was attenuated through reduction of car-
diac hypertrophy and fibrosis.96
Recent evidence implicates Ang II as a power-
ful profibrotic factor, as secreted by cFbs/myofi-
broblasts.98,99 Indeed, several independent studies 
demonstrate that exposure to Ang II stimulates cFb 
proliferation and, ultimately, fibrotic processes.97,99,100 
Cao et al observed that Ang II significantly upregu-
lated α- SMA in neonatal rat cFbs and that this cor-
related with an initial increase in Cx43 expression, 
indicative of myofibroblast activation.90 In the heart, 
myofibroblasts have been identified as a significant 
source of Ang II, implying the existence of a positive- 
feedback mechanism.100 Ang II also stimulates the 
release of TGF- β and IL- 6 from cFbs, which has been 
shown to further escalate the fibrotic process and the 
hypertrophic response seen in cardiomyocytes.99,101 
In patients with hypertensive heart disease, the 
angiotensin- converting enzyme inhibitor, lisinopril, 
reduced myocardial fibrosis, irrespective of its effects 
on left ventricular hypertrophy.102 These clinical find-
ings validate some of the preclinical evidence in favor 
of Ang II being a major driver of cardiac fibrosis.
INTERLEUKIN 6
IL- 6 is a cytokine involved in processes of differentia-
tion, growth, and survival.103 Studies show that the 
IL- 6 signaling pathway is crucial to cardiac function 
and cardioprotection following acute injury. However, 
continuous activation has been associated with at-
tenuated cardiac function attributable to processes in-
cluding cardiomyocyte hypertrophy and fibrosis.104,105 
IL- 6 is secreted by both cardiomyocytes and cFbs, 
with increased expression seen in myocardial hyper-
trophy.106,107 Although cardiomyocytes and cFbs lack 
IL- 6 receptors, local IL- 6 secretion is likely to promote 
recruitment of the inflammatory cells to myocardium. 
Indeed, IL- 6 has clearly been demonstrated to play a 
prominent role in inflammation.40,103
A study conducted by Ma et al used a macro-
phage/cFb coculture model to observe the effects 
of Ang II and IL- 6 on the activation of cFbs. They 
observed that cFbs were the main source of IL- 6 
following stimulation of Ang II and that this was re-
liant on the presence of macrophages. It was also 
determined that the presence of macrophages stim-
ulated α- SMA expression and collagen synthesis, 
and therefore activation of myofibroblasts, in an IL- 6– 
dependent manner.108 These results dictate in part a 
role for IL- 6 in cardiac fibrosis through inflammatory 
processes. However, it was subsequently demon-
strated that following cardiac injury, cardiomyocytes 
are stimulated to produce IL- 6, in turn thus stimulat-
ing proliferation of cFbs and further IL- 6 secretion. 
This feedback loop fuels cardiac fibrosis and hyper-
trophy, leading to decreased cardiac function.99,106,107 
Furthermore, Meléndez et al demonstrated that ele-
vations in IL- 6 resulted in cardiac fibrosis and a large 
degree of ventricular stiffness.40
The role of IL- 6 has also been investigated using 
complete genetic knockouts. These mice displayed 
significant differences when compared with wild 
type. The hearts were larger while also having thin-
ner chamber walls. Echocardiographic analysis 
showed cardiac dilation, implying decreased cardiac 
function. Increased collagen deposition was also ob-
served in knockout mice, along with a higher per-
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of IL- 6 led to decreased cellular interactions between 
cardiomyocytes- cFbs because of a loss of cellular ad-
hesion.104 Remarkably, a more recent study, performed 
by McArthur et al, observed an upregulation of Cx43 
expression following stimulation with IL- 6. Although this 
was only significant when in combination with the solu-
ble IL- 6 receptor, it does point to a greater involvement 
in these cellular interactions.109 This evidence supports 
the involvement of inflammation, and specifically IL- 6, 
in myocardial disorder through cardiomyocyte hyper-
trophy, fibrosis, and a loss of cardiomyocyte- cFb inter-
actions. However, mechanisms driving the sustained 
IL- 6 response that leads to these pathogenic transi-
tions are unclear and require further investigation.
ROLE OF MECHANICAL STIMULI
The Young modulus is a mechanical property that 
describes the elasticity of a material.110 The healthy 
myocardium has a Young modulus ranging from 10 to 
30 kPa.48,111,112 However, following disease or injury, the 
development of a collagenous fibrotic scar increases 
the Young modulus to ≥100 kPa.35,113 The protein α- 
SMA is associated with an increase in contractile force, 
which is needed for wound contraction following col-
lagen deposition and is therefore used as an activation 
marker for myofibroblasts.41,42
It is now commonly accepted that, under stan-
dard tissue culture conditions, because of the stiffer 
plastic surfaces (≈3  GPa), cFbs undergo activation 
to myofibroblasts. Several independent studies 
demonstrated increased expression of α- SMA after 
only a few hours of culture in rat cFbs.13,41,112 Further 
evidence for the role of mechanical signals in the 
cFb- to- myofibroblast activation process has been 
demonstrated through the use of multiple substrates 
of varying Young moduli to mimic healthy and patho-
logical cardiac environments. Use of higher Young 
moduli substrates (≥100  kPa) leads to increased 
proliferation of cFbs, higher levels of α- SMA, and 
increased deposition of collagen.41,112 How these 
mechanical signals drive the conversion to myofi-
broblast phenotype is unclear.41 Despite this, most 
studies to date use culture conditions with stiffer sur-
faces, thus presumably working with activated cFbs. 
Future studies should take into account substrate 
stiffness when designing experiments using cFbs to 
better match physiological conditions (see section 
on Cardiomyocyte and Cardiac Fibroblast In Vitro 
Culture Models). Some groups have begun to exper-
iment with polyacrylamide- or poly(ethylene glycol)- 
based hydrogels, and others are using silicone.48,114 
In addition, with several commercially sourced cul-
ture dishes with softer Young moduli available, these 
experiments are now more achievable.
As well as acting as a stimulus for activation, me-
chanical forces have also been implicated in com-
municative processes in a phenomenon known as 
mechanoelectric feedback. The effect of mechanical 
forces on cardiomyocyte- cardiomyocyte communica-
tions is relatively well investigated115,116; however, the 
role of mechanical signal transmission between cardio-
myocytes and cFbs is yet to be elucidated. Intercalated 
discs are structures found at the distal ends of cardio-
myocytes, mediating the mechanoelectric feedback 
between cardiomyocytes.117– 119 They consist of the 
fascia adherens, desmosomes, and gap junctions.117 
Fascia adherens junctions are constructed from ad-
hesion proteins, known as cadherins, that link the in-
tercalated discs to the actin cytoskeleton within the 
cardiomyocytes.118,119 Mutations in cadherins, as well 
as plakoglobin and desmoplakin, have significantly af-
fected electrical coupling.
Normal electrical coupling of cardiomyocytes has 
some dependence on normal mechanical coupling, 
and thus it is reasonable to assume that the mech-
anoelectric phenomenon also mediates heterocellu-
lar coupling of cFbs and cardiomyocytes.119,120 This 
has been evidenced in part through the application 
of pulsatile stretch, which induced higher expression 
of proteins involved in both mechanical and electrical 
coupling in neonatal rat cardiomyocytes.116 Zhuang 
et al used a custom- made stretch apparatus to apply 
10% pulsatile stretch to cells for either 6 or 72 hours. 
They observed an increase in Cx43 expression, 
which corresponded to a relatively rapid increase in 
conduction velocity. This increase in electrical cou-
pling could contribute to the formation of arrhythmia 
through dysregulated conduction in heterogeneously 
contracting cardiac tissue.116 Conversely, Thompson 
et al showed that inhibiting myofibroblast contraction 
and blocking mechanosensitive channels in mono-
layers of cocultured myofibroblasts and neonatal 
rat ventricular cardiomyocytes lead to a minimal in-
crease in myofibroblast membraneous expression of 
Cx43, a significant increase in cadherin expression, 
and an increase in conduction velocity.84 It is difficult 
to reconcile these divergent findings. Pulsatile stretch 
and reduced cellular tension are both likely to play 
a role in disease progression; however, the patho-
physiological relevance of these studies remains to 
be confirmed.
Multiple studies have also shown that growing 
cFbs or cardiomyocytes on stiffer substrates causes 
an increase in expression of proteins mediating cell- 
cell contact.84,119 N- cadherin is most commonly found 
between myofibroblasts and cardiomyocytes. By ap-
plying pulsatile stretch to cultures of cardiomyocytes 
and/or myofibroblasts, there was an upregulation in 
expression of adhesion proteins, such as N- cadherin, 
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Thompson et al have also demonstrated that reduced 
expression of N- cadherin, via short- interfering RNA, 
reversed conduction slowing by myofibroblasts.121
Multiple lines of evidence confirm that environmen-
tal stiffness affects structural and functional properties 
of the myocardium. Increased mechanical forces can 
lead to altered cardiomyocyte electrophysiological fea-
tures and pathological fibrosis.32,112 Better understand-
ing of the mechanisms and key players driving cardiac 
fibrosis is necessary if we are to develop targeted ther-
apeutic agents.
CARDIOMYOCYTE AND CFB IN VITRO 
CULTURE MODELS
Current in vitro cell culture models do not recapit-
ulate the stiffness characteristics of healthy or dis-
eased myocardium, nor do they regularly consider 
multiple cells types that exist in the heart and their 
interplay. Considering that standard plastic dishes, 
because of high tensile strength, can lead to fibro-
blast activation, some previous work may require 
validation.13,72 Indeed, activation state of the cFb can 
significantly modulate structural and functional myo-
cardial properties.13,73 cFbs and myofibroblasts (TGF- 
β– treated or α- SMA– positive cells) have differential 
effects on electrophysiological features in cardio-
myocytes. More important, in coculture with car-
diomyocytes, myofibroblasts often cause a slowing 
of conduction.73,84,121 However, defining what is the 
tensile strength of healthy human myocardium is not 
straightforward. Tensile strengths in the range of 5 to 
50 kPa have been reported.36,41,111,112 Determination 
of the Young modulus in healthy and diseased human 
myocardial tissue can be compromised by handling 
after surgery but equally by different stages of dis-
ease. Furthermore, whether the Young modulus var-
ies between the different chambers of the heart is yet 
to be investigated and should be considered moving 
forward.
Most experiments are conducted using mu-
rine cardiomyocytes and cFbs, despite significant 
differences in electrophysiological features when 
compared with humans, which have been reviewed 
extensively elsewhere.122,123 These species differ-
ences are thought to contribute to high failure rates 
of cardiac drugs in clinical trials.124 The use of human 
induced pluripotent stem cell– derived cardiomyo-
cytes (hiPSC- CMs) may circumvent these problems 
to some extent. However, hiPSC- CMs show an im-
mature phenotype, including spontaneous beating, 
reduced expression of the potassium channels, and 
a more depolarized resting membrane potential.124 
The cardiac differentiation process is also a rela-
tively lengthy one.125 Methods aimed at improving 
differentiation efficiency and hiPSC- CM yield are be-
coming routine, whereas many groups have shown 
tangible improvements in maturity.126– 128 Yang et al 
treated hiPSC- CMs for 2 weeks with fatty acids and 
observed a more mature phenotype. This included 
larger and less circular cell size and a significant 
increase in sarcomere length. Also observed were 
increases in calcium transient amplitude and twitch 
force.129 A slightly more established method is the use 
of mechanical forces during the differentiation pro-
cess. Through increased substrate stiffness or appli-
cation of stretch, several independent studies have 
demonstrated more mature characteristics.130– 132
Cellular interactions are of course also to be con-
sidered when developing a culture model for experi-
mentation. Novel methods, allowing differentiation of 
human induced pluripotent stem cell– derived cFbs, 
have been developed, opening up opportunities for 
much needed human coculture experiments.133,134 
Furthermore, the roles of other cell types are also 
beginning to be explored.20 Hulsmans et al ob-
served the presence of Cx43 at cell- cell contacts 
between cardiomyocytes and macrophages. They 
also demonstrated that, in the presence of macro-
phages, cardiomyocytes had a more depolarized 
resting membrane potential and decreased action 
potential duration.135 Use of endothelial and fibroblast 
coculture methods has also been reported to aid in 
induced pluripotent stem cell– derived cardiomyocyte 
maturation.136– 139
Consideration of the effects of ECM on cardio-
myocyte and cFb structure and function is also nec-
essary. The varying composition of the ECM can 
alter its properties, such as stiffness, and conse-
quently exert differential effects on cardiomyocytes 
and cFbs.28,35 It is therefore important to replicate 
the ECM cellular environment as closely as possi-
ble in vitro to create representative culture mod-
els. Research groups often use collagen coatings 
during cell culture as collagen is highly expressed in 
the myocardium.112 However, following injury, it has 
been demonstrated that the collagen composition 
of the ECM changes to express more collagen 1 
than collagen 3.42,140 Equally, ECM protein fibronec-
tin was shown to be required for TGF- β– induced 
myofibroblast differentiation.48 ECM also has pos-
itive effects on cardiomyocyte organization in cul-
ture, aiding in cellular alignment, similar to that seen 
in vivo. This has been demonstrated through use of 
ridged collagen plates, where cardiomyocytes are 
allowed to connect to the ECM, forming laminae.141
More frequently, hiPSC- CMs are being used in a 
3- dimensional context to mimic the more complex 
tissue environment that exists in vivo. This concept of 
cardiac tissue engineering allows interrogation of both 
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cardiomyocytes but also between other cardiac cell 
types.72,142 A recent study by Lee et al established a 
3- dimensional microtissue, using both cardiomyocytes 
and cFbs, to develop a novel model of cardiac fibro-
sis.143 Research such as this allows more accurate 
interrogation of cardiac disease and creates new plat-
forms for discovery of more tailored medicine through 
use of patient- derived models.
IS THE MYOFIBROBLAST 
PHENOTYPE REVERSIBLE?
Previously, it was thought that the myofibroblast 
was a terminally differentiated phenotype. The only 
method of reestablishing tissue homeostasis was that 
of apoptotic clearance after wound healing. However, 
more recent studies suggest that dedifferentiation or 
phenotype reversibility is possible and could hold the 
answer to identifying new therapeutic targets.47
Several pathways have been identified in the cFb- 
myofibroblast activation process, with TGF- β being the 
main target of interest. Indeed, competitive inhibition 
of TGF- β receptors leads to a decrease in expression 
of α- SMA fibers, a marker for myofibroblast activa-
tion.47,48 Other research has shown that softer sub-
strates, around or just below what would be expected 
of the healthy myocardium, also lead to a decrease 
in expression of α- SMA fibers.37,48 α- SMA expression 
levels in these studies did not return to those of qui-
escent cFbs, suggesting that there may be an inter-
mediate stage, termed the protomyofibroblast,42,144 
as observed in a liver fibrosis study.145 This cFb plas-
ticity was only demonstrated in freshly isolated cells, 
so the myofibroblast reversibility in long- term culture 
on harder substrates needs to be investigated.22,32,48 
Interestingly, a study by Nagaraju et al observed that 
myofibroblasts obtained from patients with heart failure 
had less α- SMA expression following treatment with a 
TGF- β receptor inhibitor. Whether this was dedifferen-
tiation or simply a loss of α- SMA fibers is unclear.22
Prolonged activation of myofibroblasts leads to 
sustained fibrotic processes within the myocardium, 
leading to deterioration of heart function. Fibrosis, 
although ultimately detrimental, is necessary imme-
diately following the myocardial injury, and myofibro-
blasts are a crucial part of this process. Inhibition 
of TGF- β following myocardial injury has led to in-
creased mortality in a mouse model.22 Full genetic 
knockouts of TGF- β or certain signaling components 
(ie, Smad2) have embryonic lethality.44,146 Therefore, 
reversal of the cFb- to- myofibroblast transition may 
not be an appropriate therapeutic approach for myo-
cardial injury, although it may be more useful for 
treatment of chronic CVD, thus preventing the pro-
gression toward heart failure.22
CONCLUSIONS
Studies over the past 20  years have started to 
unveil the complexity of the cell- cell interactions 
within the myocardium. In this article, we focus on 
the role of the cFb and the activated myofibroblast 
in altering the structure and function of the myo-
cardium. Yet, there are still conflicting views as to 
the effects of these 2 cell types on cardiac electro-
physiological features and whether these phenom-
ena occur in humans. To advance the work further, 
we will require use of the full range of cellular and 
animal model systems available, while acknowl-
edging the particular strengths and weaknesses 
each possesses.
There are difficulties involved with in situ experi-
mentation; there are also limitations involved with cul-
turing cFbs in vitro, in particular their propensity for 
differentiation/activation to myofibroblasts. In addition, 
considering the immaturity of hiPSC- CM models, the 
importance of developing better, more representative 
fibrosis models is necessary.
Another issue that cannot be avoided is the im-
mense complexity of the pathogenesis of fibrosis. With 
multiple different and often intersecting pathways, it 
will be difficult to identify a single valid target to reduce 
or revert the process. However, only by integrating 
existing biological and computational platforms with 
systems biology approaches will further progress be 
made. Many of these processes are conserved across 
organs and, therefore, identifying common mecha-
nisms could have huge clinical benefit for many differ-
ent diseases involving fibrosis.
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